Lilly is known as the GLP-1 company, and Zepbound and Mounjaro pulled in more than $8 billion in U.S. sales last quarter alone, so nobody had vaccines on the bingo card.
Today Lilly spent nearly $4 billion on three of them.
Lilly is buying Curevo for $1.5 billion, The Vaccine Company for $1.55 billion, and LimmaTech Biologics for $780 million - all cash, all announced the same morning.
Each company brings something different. Curevo has a new shingles shot built to be easier on the immune system, while LimmaTech targets drug-resistant bacteria like gonorrhea and chlamydia, and The Vaccine Company builds tiny-particle tech aimed at viruses including Epstein-Barr.
The strategy line came from Dan Skovronsky, Lilly's chief scientific and product officer and president, who said the goal is to stop disease at the source instead of treating it later.
That's a real pivot from a company famous for chronic drugs you take forever.
Every morning, Market Briefs breaks down moves like this in five minutes a day, and joining gets you a free investing masterclass on the side.
Lilly still owns the obesity drug market with a 60.1% U.S. share against Novo Nordisk's 39.4%. The newly approved obesity pill Foundayo rolled out in Q2 to keep pressure on Wegovy.
That kind of cash flow is what lets a company write three checks in one morning without flinching. Vaccines bring steady revenue but slower upside, so the math only works when a blockbuster is already paying for the runway.
Buying scientists, pipelines, and plants in a single morning also buys time. Building any of that in-house would take years that Lilly does not want to spend.
Big pharma has been on a buying spree all year as patent cliffs draw closer and pipelines thin out, so Lilly's move fits that pattern.
The choice of targets still stands out. Shingles, drug-resistant bacteria, and Epstein-Barr all sit on Wall Street's radar as areas with real unmet need - more on where investors see opportunity in our take on the biotech surge.
The real question is whether Lilly can run a vaccine business at the same level it runs GLP-1s, since Pfizer and Merck have decades of head start in the space.
For investors, the next milestone is trial data. Curevo's shingles vaccine still has to prove it tops the current standard, while LimmaTech and The Vaccine Company are further from approval.
The stock barely moved on the news, which usually means the market thinks the price was fair.
If you want this kind of read on the market every morning, join 350,000+ investors reading Market Briefs. You also get a 45-minute investing course thrown in as a bonus.
